Evidence map›Paper›PMID 25778891›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015

[Clinical study on 137 cases of unrelated single unit umbilical cord blood hematopoietic stem cell transplantation].

Hua Zhu, Yi Zhang, Huanying Jin, Yinting Wang, Xiayan Shao, Jingsi Kong, Wenhao Huang, Yan Hong, Chunli Li, Feng Gao and 3 more

Abstract read
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hua ZhuShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Yi ZhangShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Huanying JinShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Yinting WangShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Xiayan ShaoShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Jingsi KongShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Wenhao HuangShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Yan HongShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Chunli LiShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Feng GaoShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Liang ChenShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Feng WangShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.
Yao LuShanghai Cord Blood Bank, Shanghai Stem Cell Technology Co., LTD., Shanghai 200051, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate relevant prognostic factors of unrelated single unit umbilical cord blood hematopoietic stem cell transplantation (sUCBT), and to explore the correlation between cryopreservation time of cord blood and cell viability and outcome of sUCBT.

methodsRetrospective analysis of 137 patients undergoing sUCBT with cord blood provided by Shanghai Cord Blood Bank from Mar. 15, 2007 to Dec. 26, 2013 were performed in this study. The mean cryopreservation time of 137 units cord blood was 698(96-1968) days, with mean cell viability of 87.4% after thawing.

resultsNo statistical difference on cell viability, hematopoietic reconstitution, graft failure, acute graft versus host disease (GVHD) and overall survival (OS) was found between patients transfused with cord blood preserved below and above 2 years. The 5-year OS of patients transfused with cord blood preserved below and above 2 years were 55.6% and 67.9%, respectively (P=0.124). OS of the UCBT at 2011 and before, and after 2011 was 48.7% and 79.6%, respectively (P=0.001). Age above 16-year-old (RR=2.830, P=0.027) and UCBT at 2011 and before (RR=0.203, P<0.001) were two risk factors of treatment related mortality.

conclusionOutcome of sUCBT in China had significant improvement in recent 2 years. Cryopreservation time of cord blood had no statistical correlation to cell viability after thawing and clinical outcome.

Indexed as

Cord Blood Stem Cell TransplantationFetal BloodHematopoietic Stem Cell TransplantationCell SurvivalChinaGraft vs Host DiseaseHumansRetrospective Studies

Identifiers

PMID25778891
PMCPMC7342165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.